Darolutamide (Nubeqa) + Lupron for High Risk Prostate Cancer | Learn About Clinical Trials
4.8 هزار بار بازدید -
5 سال پیش
-
Note: This Trial is Not
Note: This Trial is Not Yet Recruiting
PCRI's Executive Director, Mark Scholz, MD, discusses a clinical trial (NCT04136353) combining first-generation hormone therapy with the second-generation agent, Nubeqa (darolutamide), for men in two different situations. First are men with high-risk disease ("Azure" at the PCRI), and, second, are men who have been treated with surgery and their PSAs failed to drop to zero or lymph node involvement was discovered at the time of surgery ("Indigo" at the PCRI).
0:24 This trial is observing 1100 men with high-risk prostate cancer to see if adding darolutamide (Nubeqa) to standard first-generation hormone therapy (Lupron) will improve outcomes. Some features of "high-risk" prostate cancer are Gleason 9 and 10, PSAs over 20, large bumps on the DRE, seminal vesicle invasion, and pelvic lymph node involvement. They are also accepting men who had surgery, but where the PSA did not drop to 0 or lymph node involvement was discovered at the time of surgery.
1:32 The trial will divide the 1100 men into two groups. One group will take Lupron plus darolutamide and the other group will take Lupron alone. The hope is that the group receiving darolutamide will have better outcomes. Darolutamide has already been FDA approved for more advanced stages of prostate cancer.
2:06 Darolutamide is also known by its trade name as Nubeqa. It is a pill that is taken twice per day. It does not have many side effects besides those that are caused by Lupron. Darolutamide is normally very expensive, maybe $10,000 a month, and so this trial is a good opportunity to get the medicine for free.
Don’t know your prostate cancer stage? Take the quiz: Visit http://www.prostatecancerstaging.org
To learn more about prostate cancer visit http://www.pcri.org
To download the free Staging Guide visit http://www.pcri.org/prostate-cancer-s...
Who we are:
The Prostate Cancer Research Institute (PCRI) is a 501(c)(3) not-for-profit organization that is dedicated to helping you research your treatment options. We understand that you have many questions, and we can help you find the answers that are specific to your case. All of our resources are designed by a multidisciplinary team of advocates and expert physicians, for patients. We believe that by educating yourself about the disease, you will have more productive interactions with your medical professionals and receive better individualized care. Feel free to explore our website or call our free helpline at 1 (800) 641-7274 with any questions that you have. Our Federal Tax ID # is 95-4617875 and qualifies for maximum charitable gift deductions by individual donors.
The information on the Prostate Cancer Research Institute's YouTube channel is provided with the understanding that the Institute is not engaged in rendering medical advice or recommendation. The information provided in these videos should not replace consultations with qualified health care professionals to meet your individual medical needs.
#ProstateCancer #Prostate#MarkScholzMD
PCRI's Executive Director, Mark Scholz, MD, discusses a clinical trial (NCT04136353) combining first-generation hormone therapy with the second-generation agent, Nubeqa (darolutamide), for men in two different situations. First are men with high-risk disease ("Azure" at the PCRI), and, second, are men who have been treated with surgery and their PSAs failed to drop to zero or lymph node involvement was discovered at the time of surgery ("Indigo" at the PCRI).
0:24 This trial is observing 1100 men with high-risk prostate cancer to see if adding darolutamide (Nubeqa) to standard first-generation hormone therapy (Lupron) will improve outcomes. Some features of "high-risk" prostate cancer are Gleason 9 and 10, PSAs over 20, large bumps on the DRE, seminal vesicle invasion, and pelvic lymph node involvement. They are also accepting men who had surgery, but where the PSA did not drop to 0 or lymph node involvement was discovered at the time of surgery.
1:32 The trial will divide the 1100 men into two groups. One group will take Lupron plus darolutamide and the other group will take Lupron alone. The hope is that the group receiving darolutamide will have better outcomes. Darolutamide has already been FDA approved for more advanced stages of prostate cancer.
2:06 Darolutamide is also known by its trade name as Nubeqa. It is a pill that is taken twice per day. It does not have many side effects besides those that are caused by Lupron. Darolutamide is normally very expensive, maybe $10,000 a month, and so this trial is a good opportunity to get the medicine for free.
Don’t know your prostate cancer stage? Take the quiz: Visit http://www.prostatecancerstaging.org
To learn more about prostate cancer visit http://www.pcri.org
To download the free Staging Guide visit http://www.pcri.org/prostate-cancer-s...
Who we are:
The Prostate Cancer Research Institute (PCRI) is a 501(c)(3) not-for-profit organization that is dedicated to helping you research your treatment options. We understand that you have many questions, and we can help you find the answers that are specific to your case. All of our resources are designed by a multidisciplinary team of advocates and expert physicians, for patients. We believe that by educating yourself about the disease, you will have more productive interactions with your medical professionals and receive better individualized care. Feel free to explore our website or call our free helpline at 1 (800) 641-7274 with any questions that you have. Our Federal Tax ID # is 95-4617875 and qualifies for maximum charitable gift deductions by individual donors.
The information on the Prostate Cancer Research Institute's YouTube channel is provided with the understanding that the Institute is not engaged in rendering medical advice or recommendation. The information provided in these videos should not replace consultations with qualified health care professionals to meet your individual medical needs.
#ProstateCancer #Prostate#MarkScholzMD
5 سال پیش
در تاریخ 1398/11/23 منتشر شده
است.
4,886
بـار بازدید شده